➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson
Express Scripts

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Patent: 10,336,816

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,336,816
Title:Phage-displayed single-chain variable fragment library
Abstract: Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, that comprised a plurality of phage-displayed scFvs characterized with (1) a specific CS combination; (2) a specific distribution of aromatic residues in each CDR; and (3) a specific sequence in each CDR. The present scFv library could be used to efficiently produce different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.
Inventor(s): Yang; An-Suei (Emeryville, CA), Chen; Hong-Sen (Taipei, TW), Chen; Ing-Chien (Taipei, TW), Tung; Chao-Ping (Taipei, TW), Hou; Shin-Chen (Taichung, TW), Yu; Chung-Ming (Taipei, TW), Yang; Chi-Kai (Taipei, TW), Chiu; Yi-Kai (Taipei, TW)
Assignee: Academia Sinica (Taipei, TW)
Application Number:15/547,523
Patent Claims:see list of patent claims

Details for Patent 10,336,816

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Academia Sinica (Taipei, TW) 2035-02-24 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Academia Sinica (Taipei, TW) 2035-02-24 RX search
Octapharma Usa Inc CUTAQUIG immunoglobulin g SOLUTION 125668 1 2019-05-03   Start Trial Academia Sinica (Taipei, TW) 2035-02-24 search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Academia Sinica (Taipei, TW) 2035-02-24 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Academia Sinica (Taipei, TW) 2035-02-24 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,336,816

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
McKesson
AstraZeneca
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.